Novavax
Trade Novavax 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About NVAX
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines.
NVAX Key Statistics
Stock Snapshot
Novavax(NVAX) stock is priced at $7.62, giving the company a market capitalization of 1.24B. It carries a P/E multiple of 3.41.
On 2025-11-06, Novavax(NVAX) stock traded between a low of $7.39 and a high of $8.03. Shares are currently priced at $7.62, which is +3.1% above the low and -5.1% below the high.
Novavax(NVAX) shares are trading with a volume of 2.67M, against a daily average of 3.4M.
In the last year, Novavax(NVAX) shares hit a 52-week high of $11.55 and a 52-week low of $5.01.
In the last year, Novavax(NVAX) shares hit a 52-week high of $11.55 and a 52-week low of $5.01.
NVAX News
Investors in Novavax, Inc. (Symbol: NVAX) saw new options begin trading today, for the December 26th expiration. At Stock Options Channel , our YieldBoost formu...
(RTTNews) - Novavax Inc. (NVAX) released Loss for its third quarter that increased from the same period last year and missed the Street estimates. The company'...
Reports Q3 revenue $70.45M, consensus $44.87M. “We have continued the steady transformation of Novavax (NVAX) and are proud of our progress this quarter,” said...
Analyst ratings
56%
of 9 ratingsMore NVAX News
Wondering if Novavax is a bargain or a big risk right now? You are not alone; there is plenty of debate around whether the current price reflects the company's...
TD Cowen lowered the firm’s price target on Novavax (NVAX) to $7 from $8 and keeps a Hold rating on the shares. The firm updated its model ahead of Q3 results t...
Novavax (NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid to Sanofi (SNY), enabling Sanofi to take full...
On October 7, Novavax completed the transfer of its COVID-19 vaccine, Nuvaxovid, to Sanofi, granting Sanofi full commercial and regulatory responsibility for th...